NCT03345485: Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors

NCT03345485
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: 
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with primary central nervous system (CNS) cancer
https://ClinicalTrials.gov/show/NCT03345485

Comments are closed.

Up ↑